share_log

Benuvia To Go Public Via SPAC Deal With Pono Capital, Deal Valued At $440M

Benuvia To Go Public Via SPAC Deal With Pono Capital, Deal Valued At $440M

Benuvia 将通过 SPAC 与 Pono Capital 的交易上市,交易价值4.4亿美元
Benzinga Real-time News ·  2022/03/18 06:07
Benuvia, a leading drug developer focused on pharmaceutical cannabinoids has entered into a definitive business combination agreement with Pono Capital Corp (NASDAQ:PONO) The transaction implies a combined company pro forma enterprise value of $440 million Benuvia owns SYNDROS®, the FDA approved dronabinol (THC) oral solution, CII, which is approved for chemotherapy-induced nausea and vomiting in cancer patients and loss of appetite in AIDS patients who have lost weight, and is pursuing three additional INDs based on the same formulation as SYNDROS® Benuvia manufactures active pharmaceutical ingredients in its 83,000 square foot manufacturing facility that is permitted by the US DEA...
贝努维亚, 一家专注于药物大麻素的领先药物开发商 已与之签订了最终的业务合并协议 波诺 资本公司 (纳斯达克股票代码:PONO) 该交易意味着合并后的公司预计企业价值为 4.4 亿美元n 贝努...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发